Gliris-M1 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The prolonged-release formulation ensures a steady plasma concentration, improving glycemic control and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Gliris-M1 Forte Tablet PR is prescribed as an adjunct to diet and exercise to achieve optimal blood glucose regulation in patients inadequately controlled with monotherapy or lifestyle modifications alone. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised in elderly patients and those with cardiovascular disease. Regular monitoring of blood glucose, renal function, and hepatic parameters is essential during therapy. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rare lactic acidosis. Patient education on adherence, diet, and recognition of hypoglycemia symptoms is critical for effective and safe treatment outcomes.